1342037
USP
Insulin aspart
United States Pharmacopeia (USP) Reference Standard
About This Item
API family
insulin
form
solid
manufacturer/tradename
USP
application(s)
USP Biologics
pharmaceutical (small molecule)
pharmaceutical
General description
Insulin Aspart is a rapid-acting insulin analog produced by recombinant DNA technology. It differs from human insulin by a single amino acid substitution, enhancing its absorption rate. This modification allows for improved postprandial glucose control in diabetic patients.
The USP biologics proteins category provides critical standards and reference materials necessary for the development and manufacturing of therapeutic proteins. These proteins, which can be naturally derived or genetically engineered, are essential in treating various diseases and conditions, ensuring that they meet quality, safety, and efficacy standards.
The United States Pharmacopeia (USP) provides quality standards for biologics to ensure their safety, efficacy, and quality throughout the manufacturing process. These standards assist manufacturers in adhering to regulatory requirements and help safeguard public health by reducing risks associated with biologics.
Application
- Insulin Aspart Injection
Analysis Note
Other Notes
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
If you need assistance, please contact Customer Support
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service